Christopher Lin
Ophthalmology · Eureka, CANPI 1811982291
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,300 of the $5,356 with a category attached, or 61.6%. AbbVie accounts for 73.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $2,795 and has fallen 90.4% since, to $269 in 2023.
Across 52 payments — averaging $103.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Glaukos Corporation$576
- Ivantis, Inc$374
- Optos, Inc.$117
- Aerie Pharmaceuticals, Inc.$113
- Alcon$95
- plus $149 from 5 others
Across 173 payments — averaging $1153.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$103K
- Glaukos Corporation$94K
- Ocular Therapeutix, Inc.$3K
What the payments were for
- Consulting fees$1503%
- Speaking & faculty fees$3,30062%
- Travel & lodging$2284%
- Food & beverage$1,54529%
- Gifts$170%
- Entertainment$1172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $3,933 |
| Glaukos Corporation | 11 | $576 |
| Ivantis, Inc | 4 | $374 |
| Optos, Inc. | 1 | $117 |
| Aerie Pharmaceuticals, Inc. | 3 | $113 |
| Alcon | 2 | $95 |
| Sight Sciences, Inc. | 5 | $82 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Omeros Corporation | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,357 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 111 | $67,695 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $11,556 |
| RhopressaNetarsudil Mesylate | 14 | $7,045 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $6,734 |
| Alphagan PBrimonidine Tartrate | 13 | $5,891 |
| Brinzolamide | 13 | $2,907 |
| Latanoprost | 186 | $2,714 |
| Travoprost | 11 | $1,507 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,289 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $994 |
| Timolol Maleate | 64 | $735 |
| Brimonidine Tartrate | 31 | $381 |
| Dorzolamide Hcl | 13 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $3,933 | $80,320141 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $113 | $18,60041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Eureka
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.